Show simple item record

dc.contributor.authorCastillo, RL
dc.contributor.authorIbacache, M
dc.contributor.authorCortínez, I
dc.contributor.authorCarrasco-Pozo, C
dc.contributor.authorFarías, JG
dc.contributor.authorCarrasco, RA
dc.contributor.authorVargas-Errázuriz, P
dc.contributor.authorRamos, D
dc.contributor.authorBenavente, R
dc.contributor.authorTorres, DH
dc.contributor.authorMéndez, A
dc.date.accessioned2020-09-11T05:23:52Z
dc.date.available2020-09-11T05:23:52Z
dc.date.issued2020
dc.identifier.issn1663-9812
dc.identifier.doi10.3389/fphar.2019.01641
dc.identifier.urihttp://hdl.handle.net/10072/397404
dc.description.abstractDexmedetomidine (DEX) is a highly selective α2-adrenergic agonist with sedative and analgesic properties, with minimal respiratory effects. It is used as a sedative in the intensive care unit and the operating room. The opioid-sparing effect and the absence of respiratory effects make dexmedetomidine an attractive adjuvant drug for anesthesia in obese patients who are at an increased risk for postoperative respiratory complications. The pharmacodynamic effects on the cardiovascular system are known; however the mechanisms that induce cardioprotection are still under study. Regarding the pharmacokinetics properties, this drug is extensively metabolized in the liver by the uridine diphosphate glucuronosyltransferases. It has a relatively high hepatic extraction ratio, and therefore, its metabolism is dependent on liver blood flow. This review shows, from a basic clinical approach, the evidence supporting the use of dexmedetomidine in different settings, from its use in animal models of ischemia-reperfusion, and cardioprotective signaling pathways. In addition, pharmacokinetics and pharmacodynamics studies in obese subjects and the management of patients subjected to mechanical ventilation are described. Moreover, the clinical efficacy of delirium incidence in patients with indication of non-invasive ventilation is shown. Finally, the available evidence from DEX is described by a group of Chilean pharmacologists and clinicians who have worked for more than 10 years on DEX.
dc.description.peerreviewedYes
dc.publisherFrontiers Media SA
dc.relation.ispartofpagefrom1641
dc.relation.ispartofjournalFrontiers in Pharmacology
dc.relation.ispartofvolume10
dc.subject.fieldofresearchPharmacology and pharmaceutical sciences
dc.subject.fieldofresearchcode3214
dc.titleDexmedetomidine Improves Cardiovascular and Ventilatory Outcomes in Critically Ill Patients: Basic and Clinical Approaches
dc.typeJournal article
dc.type.descriptionC1 - Articles
dcterms.bibliographicCitationCastillo, RL; Ibacache, M; Cortínez, I; Carrasco-Pozo, C; Farías, JG; Carrasco, RA; Vargas-Errázuriz, P; Ramos, D; Benavente, R; Torres, DH; Méndez, A, Dexmedetomidine Improves Cardiovascular and Ventilatory Outcomes in Critically Ill Patients: Basic and Clinical Approaches, Frontiers in Pharmacology, 2020, 10, pp. 1641
dc.date.updated2020-09-11T05:20:01Z
dc.description.versionVersion of Record (VoR)
gro.hasfulltextFull Text
gro.griffith.authorCarrasco Pozo, Catalina A.


Files in this item

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record